Advertisement

Search Results

Advertisement



Your search for The matches 32821 pages

Showing 1 - 50


pancreatic cancer
issues in oncology

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Researchers have identified a novel strategy to screen for pancreatic cancer in high-risk patients, according to a recent study published by Zogopoulos et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings demonstrated the feasibility of improving the early detection and ...

breast cancer
colorectal cancer
lung cancer
issues in oncology

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities

Investigators have found a higher rate of mortality among patients with intellectual and developmental disabilities diagnosed with breast cancer, colorectal cancer, or lung cancer, according to a recent study published by Hansford et al in the Canadian Journal of Public Health. Study Methods and...

breast cancer

Risk of Second Primary Breast Cancer in Young Breast Cancer Survivors

In a study reported in JAMA Oncology, Kristen D. Brantley, PhD, MPH, and colleagues identified the risk of a second primary breast cancer among survivors of breast cancer diagnosed at age 40 or younger, including among women with and without germline pathogenic variants. Study Details The study...

pain management

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

  Pain, a debilitating consequence of cancer and its treatments, is highly prevalent among patients with advanced cancer.1 Often persistent and undertreated, it is associated with poor functional and emotional well-being and typically occurs along with insomnia and fatigue.2 The use of opioids,...

multiple myeloma

Natalie S. Callander, MD, on Multiple Myeloma: Management Updates

Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses advances in the treatment of patients with multiple myeloma, including her commentary on smoldering disease, the early use of CAR T-cell therapy, quadruplet therapy, and the use of multiple lines of treatment...

breast cancer

William J. Gradishar, MD, on HR-Positive, HER2-Negative Breast Cancer: Management Update

William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, details the fundamental shift in how clinicians now treat patients with endocrine-sensitive breast cancer, both advanced and early stage, by pairing antihormonal therapy with targeted treatment.

kidney cancer

Metastatic RCC After Disease Progression on VEGF/IO Therapy

This is Part 3 of Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Rana McKay, Bradley McGregor, and Sumanta K. Pal discuss the management of metastatic...

kidney cancer

Refractory RCC After Disease Progression on Adjuvant IO Therapy

This is Part 2 of Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Rana McKay, Bradley McGregor, and Sumanta K. Pal discuss the management of refractory...

kidney cancer

Metastatic Favorable-Risk RCC After Progression on VEGF/IO Therapy

This is Part 1 of Later-Line Considerations in Relapsed/Refractory Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Rana McKay, Bradley McGregor, and Sumanta K. Pal discuss the management of metastatic...

skin cancer
immunotherapy

Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy

Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies the risk factors associated with overall survival and treatment failure (Abstract 60).

skin cancer
immunotherapy
issues in oncology

Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma

Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to...

breast cancer
issues in oncology

The Lancet Commission on Breast Cancer: Reducing Overlooked Inequities in Breast Cancer

Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival, according to a recent report from The Lancet Breast Cancer Commission. These findings were published by Coles...

breast cancer
global cancer care

A Pioneering Female Oncologist in Morocco Helps Advance the Global Shift Toward Gender Equity in Academia

Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation of researchers and practitioners and enrich global oncology. I recently had the privilege to speak with Ouissam Al Jarroudi, MD, about her...

gynecologic cancers

Cisplatin, Gemcitabine, and IMRT in Locally Advanced Vulvar Cancer

In a phase II trial (NRG Oncology/GOG Study 279) reported in the Journal of Clinical Oncology, Horowitz et al found that concurrent cisplatin, gemcitabine, and intensity-modulated radiation therapy (IMRT) produced a high rate of complete pathologic response in patients with locally advanced vulvar...

breast cancer

HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy

In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive disease–free survival results in patients with HER2-positive early...

solid tumors

Cabozantinib in Advanced Adrenocortical Carcinoma

In a single-center phase II trial reported in The Lancet Oncology, Campbell et al found that cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma. Study Details In the trial, 18 patients enrolled at The University of Texas MD Anderson Cancer Center...

lung cancer

ALK-Positive NSCLC: Adjuvant Alectinib vs Platinum-Based Chemotherapy

As reported in The New England Journal of Medicine by Yi-Long Wu, MD, and colleagues, the phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy in patients with resected ALK-positive NSCLC. Study Details In the...

lung cancer

Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with atezolizumab plus cabozantinib vs docetaxel after checkpoint inhibitor treatment and chemotherapy in patients with...

gynecologic cancers

Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer

The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous recombination deficiency (HRD)-positive tumors, according to data presented during the Society of...

thyroid cancer

New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk

Glucagon-like peptide (GLP)-1 receptor agonists may not be associated with an increased risk of thyroid cancer, according to a recent study published by Pasternak et al in the BMJ. Background GLP-1 receptor agonists are designed to reduce blood sugar levels and appetite. They have become...

gynecologic cancers
genomics/genetics

Study Identifies Genetic Variants Potentially Linked to Prevalent or Persistent HPV Infections

Investigators have uncovered genetic variants that may predispose certain female patients to prevalent or persistent human papillomavirus (HPV) infections and increase their risk of developing cervical cancer, according to a recent study published by Adebamowo et al in the European Journal of Human ...

geriatric oncology

Exploring Geriatric Assessment Effectiveness: Insights From the 2023 International Society of Geriatric Oncology Conference

Geriatric assessment has emerged as a pivotal tool in optimizing cancer care for older patients, aiming to mitigate treatment toxicity, enhance treatment adherence, and improve quality of life. The recommended areas for evaluation in a geriatric assessment focus on identifying health issues that...

head and neck cancer

Newly Diagnosed Locally Advanced HNSCC: Adding Pembrolizumab to Concurrent Chemoradiotherapy

As reported in The Lancet Oncology by Jean-Pascal Machiels, MD, and colleagues, the phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with high-risk locally advanced...

colorectal cancer
geriatric oncology

Oxaliplatin-Based Adjuvant Therapy in Older Patients With Stage III Colon Cancer

In a pooled analysis of data from clinical trials in the ACCENT/IDEA databases reported in the Journal of Clinical Oncology, Claire Gallois, MD, and colleagues found that patients aged ≥ 70 years receiving oxaliplatin-based adjuvant chemotherapy for stage III colon cancer had a similar time to...

breast cancer

Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone

As reported in The New England Journal of Medicine by de Boniface et al, the phase III SENOMAC trial showed noninferiority in recurrence-free survival with sentinel node biopsy alone vs completion axillary node dissection in patients with breast cancer and sentinel node metastases. Study Details In ...

skin cancer
issues in oncology

Illuminating a Potential Culprit in Melanoma Treatment Resistance

Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma, according to a recent study published by Aya Moreno et al in Cell Reports. Background The global incidence of melanoma—the deadliest type of skin cancer—is rising, making novel...

lung cancer
issues in oncology

Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers

Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)....

lymphoma

B-Cell Non-Hodgkin Lymphoma: Extended Follow-up With Mosunetuzumab

As reported in the Journal of Clinical Oncology by L. Elizabeth Budde, MD, PhD, and colleagues, extended follow-up of the dose-escalation phase of a phase I/II trial showed that the CD20 x CD3 T-cell–engaging bispecific antibody mosunetuzumab-axgb—given as an off-the-shelf fixed-duration outpatient ...

lung cancer

Lung Cancer Screening Eligibility: Effect of Using History vs Pack-Year History of Smoking

In a study reported in the Journal of Clinical Oncology, Potter et al found that use of a smoking history of ≥ 20 years rather than the current 2021 U.S. Preventive Services Task Force (USPSTF) guideline of ≥ 20 pack-years would increase the eligibility of Black individuals for lung cancer...

bladder cancer
issues in oncology

Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer

Researchers have found that a novel urine biomarker test may effectively halve the number of cystoscopies necessary in high-risk patients with bladder cancer, according to recent findings presented by Dreyer et al at the European Association of Urology (EAU) Congress 2024. The research also...

prostate cancer
issues in oncology

Longer Interval May Be Safe for Prostate Cancer Screening in Low-Risk Patients

Undergoing a prostate-specific antigen (PSA) blood test every 5 years may be adequate for screening low-risk men for prostate cancer, according to recent findings presented by Albers et al at the European Association of Urology (EAU) Congress 2024 and simultaneously published in European Urology....

prostate cancer
global cancer care

The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040

Investigators have projected impending increases in the incidence and mortality rates of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to improve screening, awareness, research diversification, and treatment in a recent The Lancet...

skin cancer
immunotherapy

Jenny H. Chang, MD, on New Findings on Merkel Cell Carcinoma and Neoadjuvant Immunotherapy

Jenny H. Chang, MD, of the Cleveland Clinic, discusses the current surgical and radiologic treatment paradigm for patients with stage III Merkel cell carcinoma and the potential for neoadjuvant immunotherapy to help manage the disease and regional lymph node metastases (Abstract 67).

gynecologic cancers

Blood-Based Machine-Learning Assay May Noninvasively Detect Early Ovarian Cancer

Ovarian cancer is the eighth most-common cancer among women globally, and the eighth most-common cause of death from cancer worldwide. In the United States alone, in 2023, there were nearly 20,000 new cases of the cancer, and about 13,270 deaths from the disease. Ovarian cancer is largely...

supportive care
survivorship

Effect of Virtually Delivered CBT for Insomnia on Cancer-Related Cognitive Impairment

In a Canadian study reported in the Journal of Clinical Oncology, Sheila N. Garland, PhD, and colleagues found that virtually delivered cognitive behavioral therapy for insomnia (CBT-I) improved perceived cancer-related cognitive impairment (CRCI) vs waiting list controls in cancer survivors. Study ...

leukemia
immunotherapy

Anti-CD19 CAR T-Cell Therapy for Richter Transformation

In a retrospective study reported in the Journal of Clinical Oncology, Kittai et al found that anti-CD19 chimeric antigen receptor (CAR) T-cell therapy showed activity in previously treated patients with Richter transformation. Study Details In the study, 69 patients who received CAR T-cell therapy ...

prostate cancer
issues in oncology

Educational Videos May Encourage Prostate Cancer Screening Among Black Patients

Use of culturally sensitive educational videos may boost knowledge and decrease uncertainty regarding prostate cancer and screening among Black individuals, according to new findings presented by Jones et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...

solid tumors
genomics/genetics

BAP1 Mutations May Increase Susceptibility to Asbestos-Induced Malignant Mesothelioma

Researchers have shown that even minimal exposure to chrysotile asbestos may increase susceptibility to the development of malignant mesothelioma in mice with BAP1 germline mutations, according to new findings presented by Kadariya et al at the American Association for Cancer Research (AACR) Annual ...

gynecologic cancers

Ana Oaknin, MD, PhD, on Recurrent Cervical Cancer: New Findings on Atezolizumab, Bevacizumab, and Chemotherapy

Ana Oaknin, MD, PhD, of Spain’s Vall d’Hebron University Hospital, discusses phase III findings from the BEATcc trial, showing that adding atezolizumab to a standard bevacizumab-plus-platinum regimen for patients with metastatic, persistent, or recurrent cervical cancer significantly improves...

pancreatic cancer

An Exosome-Based Liquid Biopsy for Early Detection of Pancreatic Cancer

An investigational exosome-based liquid biopsy accurately detected 97% of stage I to II pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract 3899). “Pancreatic cancer is one...

prostate cancer
genomics/genetics

Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations

Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...

issues in oncology

AACR Inaugurates New Leadership

The members of the American Association for Cancer Research (AACR) elected a new 2024 to 2025 President and President-Elect at the AACR’s Annual Business Meeting of Members during the AACR Annual Meeting 2024 in San Diego. New President The AACR welcomed Patricia M. LoRusso, DO, PhD (hc), FAACR, as ...

breast cancer
genomics/genetics

PARP1-Selective Inhibitor in HRR-Deficient Breast Cancer

The novel poly-ADP ribose polymerase-1 (PARP1)-selective inhibitor saruparib demonstrated early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancer, according to new findings presented by Yap et al at the American Association for...

head and neck cancer

Investigational Personalized Vaccine in Resected Head and Neck Cancers

TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected human papillomavirus (HPV)-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association...

cns cancers

ATM Kinase Inhibitor Plus Radiotherapy for Patients With Glioblastoma

AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in patients with both recurrent and newly diagnosed glioblastoma when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in patients with recurrent...

colorectal cancer

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of the KRAS G12C inhibitor adagrasib and the anti-EGFR antibody cetuximab showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1...

prostate cancer
immunotherapy

Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer

SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer, according to results reported at the...

pancreatic cancer

Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate With Clinical Benefit

An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk of disease recurrence in certain patients with resectable pancreatic cancer,...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...

skin cancer
immunotherapy

RP1 Immunotherapy in Solid Organ Transplant Recipients With Skin Cancer

A novel oncolytic immunotherapy may show antitumor activity in solid organ transplant recipients with skin cancer, according to new findings presented by Migden et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT003). Background "Organ transplant recipients ...

Advertisement

Advertisement




Advertisement